Journal of Pediatric Hematology/Oncology最新文献_第6页

Clinical Features and Treatment Results in Children With Head and Neck Rhabdomyosarcoma. 儿童头颈部横纹肌肉瘤的临床特点及治疗效果。

IF 0.9 4区医学

Journal of Pediatric Hematology/Oncology Pub Date : 2025-08-01 Epub Date: 2025-07-02 DOI: 10.1097/MPH.0000000000003078

Ibrahim Halil Karahan, Tezer Kutluk, Bilgehan Yalcin, Burca Aydin, Nilgun Kurucu, Melis Gultekin, Ferah Yildiz, Diclehan Orhan, Gokhan Gedikoglu, Ali Varan

{"title":"Clinical Features and Treatment Results in Children With Head and Neck Rhabdomyosarcoma.","authors":"Ibrahim Halil Karahan, Tezer Kutluk, Bilgehan Yalcin, Burca Aydin, Nilgun Kurucu, Melis Gultekin, Ferah Yildiz, Diclehan Orhan, Gokhan Gedikoglu, Ali Varan","doi":"10.1097/MPH.0000000000003078","DOIUrl":"10.1097/MPH.0000000000003078","url":null,"abstract":"Rhabdomyosarcoma constitutes 3% to 4% of childhood cancers, with nearly half seen in the head and neck location. We aimed to investigate the clinical features and treatment outcomes of 65 children diagnosed and treated for head and neck rhabdomyosarcoma (RMS) between 2004 and 2018. The median age was 5.8 years with a 37:28 M/F ratio. The primary location was parameningeal in 49.2%, orbital in 35.4%, and other nonparameningeal in 15.4% patients. The most common histopathologic subtype was the embryonal subtype (73.8%). The chemotherapy regimens of CDCV (cisplatin, doxorubicin, cyclophosphamide, vincristine); VAC/VAdrC (vincristine, actinomycin-D, cyclophosphamide/vincristine, doxorubicin, cyclophosphamide); PIAV (ifosfamide, cisplatin, vincristine, doxorubicin); and VDC/IE (vincristine, doxorubicin, cyclophosphamide, ifosfamide, etoposide) were used depending on the years of diagnosis. The tumor location, risk grouping, and stage were found as the significant prognostic factors. The 5-year event-free survival (EFS) rate for all patients 41.2% and the overall survival (OS) rate was 59.3%. The 5-year OS rates were 85.2% and 80% in the orbital and other nonparameningeal RMS, respectively, it was 34.2% in the parameningeal RMS patients ( P =0.01). The patients with advanced stage, parameningeal disease have poor prognosis. New treatment approaches should be investigated to improve the outcomes in these groups.","PeriodicalId":16693,"journal":{"name":"Journal of Pediatric Hematology/Oncology","volume":" ","pages":"e241-e246"},"PeriodicalIF":0.9,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144540610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Iohexol Clearance and Biomarker Analysis to Predict Toxicity in Patients With Acute Lymphoblastic Leukemia and Lymphoma Receiving High-dose Methotrexate. 碘己醇清除率和生物标志物分析预测急性淋巴细胞白血病和淋巴瘤患者接受高剂量甲氨蝶呤的毒性。

IF 0.9 4区医学

Journal of Pediatric Hematology/Oncology Pub Date : 2025-08-01 Epub Date: 2025-06-23 DOI: 10.1097/MPH.0000000000003075

Amy L Walz, Masha Kocherginsky, Monica Newmark, Ellen Brooks, David Walterhouse

{"title":"Iohexol Clearance and Biomarker Analysis to Predict Toxicity in Patients With Acute Lymphoblastic Leukemia and Lymphoma Receiving High-dose Methotrexate.","authors":"Amy L Walz, Masha Kocherginsky, Monica Newmark, Ellen Brooks, David Walterhouse","doi":"10.1097/MPH.0000000000003075","DOIUrl":"10.1097/MPH.0000000000003075","url":null,"abstract":"Background: High-dose methotrexate (HDMTX) remains integral to acute lymphoblastic leukemia/lymphoma (ALL) treatment. However, high MTX concentrations can lead to acute kidney injury (KI) and other toxicities. We investigated whether measured GFR (mGFR) by iohexol clearance better predicts delayed MTX excretion and/or toxicity compared with standard of care using an estimated GFR (eGFR). We also examined if KI biomarkers (urine KIM-1 and clusterin, serum cystatin C, and plasma FGF23) identify KI more frequently than serum creatinine (sCr) alone.Procedure: ALL patients receive 4 doses of HDMTX with alkalinized IV fluids, leucovorin rescue, and MTX clearance per the standard of care. We obtained mGFRs before HDMTX doses 1 and 4. eGFR was calculated using the Schwartz formula and biomarkers of KI were collected around each HDMTX dose.Results: Overall, there were some associations between the mGFR/biomarkers with KI and other toxicities, but mGFR was not found to be a better predictor of delayed MTX clearance or toxicity than eGFR. The biomarkers did not predict KI development more frequently than sCr alone.Conclusions: On the basis of this study, there is no evidence that the current standard of care for determining the GFR in advance of HDMTX administration, nor postadministration management, should be adjusted.","PeriodicalId":16693,"journal":{"name":"Journal of Pediatric Hematology/Oncology","volume":" ","pages":"e235-e240"},"PeriodicalIF":0.9,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144475743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Early Versus Late Discontinuation of Empirical Antibiotics in Pediatric Oncology Patients With Fever and Neutropenia. 发热和中性粒细胞减少症儿童肿瘤患者早期与晚期停用经验性抗生素的比较。

IF 0.9 4区医学

Journal of Pediatric Hematology/Oncology Pub Date : 2025-08-01 Epub Date: 2025-06-25 DOI: 10.1097/MPH.0000000000003076

Mahdi Asleh, Carmel Levi, Yusif Abu Alhasan, Hagit Miskin, Dana Danino

引用次数: 0

Concurrent Case of Glucose-6-Phosphate Deficiency and Dehydrated Hereditary Stomatocytosis in a 4-Month-old Boy. 葡萄糖-6-磷酸缺乏并发脱水遗传性口细胞增多症1例4月龄男婴。

IF 0.9 4区医学

Journal of Pediatric Hematology/Oncology Pub Date : 2025-08-01 Epub Date: 2025-05-29 DOI: 10.1097/MPH.0000000000003057

Thao Minh Nguyen, Sara Sadiq, Joshua M Peterson, Leonard K Wang, Gulrukh Botiralieva, Yaroslav Chernov, Akila Muthukumar, Kirill A Lyapichev

{"title":"Concurrent Case of Glucose-6-Phosphate Deficiency and Dehydrated Hereditary Stomatocytosis in a 4-Month-old Boy.","authors":"Thao Minh Nguyen, Sara Sadiq, Joshua M Peterson, Leonard K Wang, Gulrukh Botiralieva, Yaroslav Chernov, Akila Muthukumar, Kirill A Lyapichev","doi":"10.1097/MPH.0000000000003057","DOIUrl":"10.1097/MPH.0000000000003057","url":null,"abstract":"Glucose-6-phosphate (G6PD) deficiency is the most prevalent enzyme deficiency and is estimated to affect 400 million people. The patients are usually asymptomatic and diagnosed following hemolytic episodes triggered by oxidative stress. Another type of hemolytic anemia known as dehydrated hereditary stomatocytosis (DHSt) is estimated to affect less than 1 per 1,000,000 people. DHSt is caused by increased cation efflux and dehydration in red blood cells, which leads to decreased flexibility making them more vulnerable to lysis. Compared with G6PD, DHSt has a mild presentation, where most patients (84%) with isolated DHSt exhibit chronic hemolysis. Both diseases, G6PD deficiency and DHSt, are inherited hemolytic anemias and to the best of our knowledge have never been reported to coexist in the same patient. Herein, we present the first case of concurrent G6PD deficiency and DHS in a 4-month-old male. We discuss the clinical presentation and hematopathology findings from this patient as well as provide a comparison literature review. We believe this presentation will add to the current body of knowledge for these conditions and help to guide future investigation and management.","PeriodicalId":16693,"journal":{"name":"Journal of Pediatric Hematology/Oncology","volume":" ","pages":"e278-e281"},"PeriodicalIF":0.9,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144248389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adjuvant Etoposide for Very High-risk PFA Ependymoma: A Case Report. 依托泊苷辅助治疗高危PFA室管膜瘤1例。

IF 0.9 4区医学

Journal of Pediatric Hematology/Oncology Pub Date : 2025-08-01 Epub Date: 2025-07-01 DOI: 10.1097/MPH.0000000000003080

Jacob Silverman, Melissa Mégalli, Emilie Giguère, Sarah Elbaz, Melanie Letourneau, Catherine Achim, Cynthia Hawkins, William Legallou, Panagiota Giannakouros, Sébastien Perreault, Geneviève Legault, Eric Bouffet, Nada Jabado, Hallie Coltin, Louis Crevier, Samuele Renzi

引用次数: 0

Hypercalcemia of Malignancy in Pediatric Population: Clinical Challenges Explored Through Cases-A Case Series. 儿童恶性肿瘤高钙血症：通过病例系列探讨临床挑战。

IF 0.9 4区医学

Journal of Pediatric Hematology/Oncology Pub Date : 2025-08-01 Epub Date: 2025-06-30 DOI: 10.1097/MPH.0000000000003079

Alpas Anand, Neha Goel, Amitabh Singh, Prashant Prabhakar, Meghna Kumari, Hashmat Singh, Suruchi Viz, Nidhi Chopra, Sumit Mehndiratta

{"title":"Hypercalcemia of Malignancy in Pediatric Population: Clinical Challenges Explored Through Cases-A Case Series.","authors":"Alpas Anand, Neha Goel, Amitabh Singh, Prashant Prabhakar, Meghna Kumari, Hashmat Singh, Suruchi Viz, Nidhi Chopra, Sumit Mehndiratta","doi":"10.1097/MPH.0000000000003079","DOIUrl":"10.1097/MPH.0000000000003079","url":null,"abstract":"Background: Hypercalcemia is an uncommon but clinically significant complication of pediatric malignancies that often presents with symptoms. However, in this case series, we report 4 children with nonspecific symptoms of hypercalcemia detected incidentally on routine biochemical evaluation at the time of leukemia diagnosis.Case presentation: Patients, 5 to 9 years of age, had underlying malignancies, including Hodgkin lymphoma (stage IIA), pre-B-cell acute lymphoblastic leukemia, and acute promyelocytic leukemia. All the patients presented with severe hypercalcemia, necessitating prompt intervention. Treatment consisted of hyperhydration, loop diuretics, bisphosphonates, and calcitonin, along with the management of the underlying malignancy. Successful resolution of hypercalcemia was achieved in all cases, with no future recurrence.Conclusion: This case series highlights the importance of the routine biochemical screening for newly diagnosed pediatric malignancies, particularly for nonspecific symptoms of hypercalcemia, which may otherwise go unrecognized. Although hypercalcemia in hematological malignancies is well-documented, our findings stress the silent presentation and reinforce the clinical need for early identification to avoid metabolic complications.","PeriodicalId":16693,"journal":{"name":"Journal of Pediatric Hematology/Oncology","volume":"47 6","pages":"e254-e259"},"PeriodicalIF":0.9,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144698890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-life Use of IV Naxitamab for Children With Relapsed/Refractory Neuroblastoma. 静脉注射纳西他单抗治疗复发/难治性神经母细胞瘤儿童的临床应用

IF 0.9 4区医学

Journal of Pediatric Hematology/Oncology Pub Date : 2025-08-01 Epub Date: 2025-07-24 DOI: 10.1097/MPH.0000000000003081

Iris Fried, Michael Weintraub, Dalia Waldman, Shoshana Revel-Vilk

引用次数: 0

Calcineurin-Inhibitor-Induced Pain Syndrome. 钙调磷酸酶抑制剂引起的疼痛综合征。

IF 0.9 4区医学

Journal of Pediatric Hematology/Oncology Pub Date : 2025-08-01 Epub Date: 2025-06-18 DOI: 10.1097/MPH.0000000000003068

Yu Furui, Shoji Saito

引用次数: 0

Ovarian Mitotically Active Cellular Fibroma of Childhood: Review of Literature and Report of a Case. 儿童卵巢有丝分裂活性细胞纤维瘤：文献回顾及1例报告。

IF 0.9 4区医学

Journal of Pediatric Hematology/Oncology Pub Date : 2025-08-01 Epub Date: 2025-06-04 DOI: 10.1097/MPH.0000000000003059

Aileen Azari-Yam, Sahar Montazeri, Bahar Ashjaei, Soheila Sarmadi

引用次数: 0

Adolescent and Young Adult Oncology in the United States in 2025: Finding Its Place in the Oncology World-Part 1 of 2. 2025年美国的青少年和年轻成人（AYA）肿瘤学：在肿瘤学领域找到自己的位置（2集之一）。

IF 0.9 4区医学

Journal of Pediatric Hematology/Oncology Pub Date : 2025-08-01 Epub Date: 2025-06-20 DOI: 10.1097/MPH.0000000000003067

Peter H Shaw, Sharon M Castellino, Jonathan Metts, Ryan Guerrettaz, Brandon Hayes-Lattin, Hong De Sa, Archie Bleyer

{"title":"Adolescent and Young Adult Oncology in the United States in 2025: Finding Its Place in the Oncology World-Part 1 of 2.","authors":"Peter H Shaw, Sharon M Castellino, Jonathan Metts, Ryan Guerrettaz, Brandon Hayes-Lattin, Hong De Sa, Archie Bleyer","doi":"10.1097/MPH.0000000000003067","DOIUrl":"10.1097/MPH.0000000000003067","url":null,"abstract":"In 2015 this core of authors wrote a \"state of the union\" overview of AYA oncology care at the time titled \"Adolescent and Young Adult (AYA) Oncology in the United States: A Specialty in Its Late Adolescence.\" Since then, the landscape of cancer care in this unique population has changed, with encouraging improvement in some areas and persistent challenges in others. Nine years later, we have decided to update our review to demonstrate how far we have come in caring for 15 to 39-year olds with cancer in the United States and how much further we need to go to truly improve both their short-term and long-term outcomes. What started as a call to arms after the AYA-specific Progress Review Group (PRG) in 2006 became a national initiative, which has had successes and failures nationally, regionally, and locally in trying to move the needle for a group of patients that continues to straddle both the pediatric and adult oncology worlds. Back in 2015, we described the field as in its late adolescence, still trying to define itself. With this 2-part review, we hope to demonstrate that as a subspecialty it has grown up but is still trying to firmly establish its place in the larger world of oncology, much like a young adult that has moved away from home and is establishing its own identity in a changing world. In part 1 we focus on epidemiology of AYA cancer as well as acute lymphoblastic leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, and sarcoma in this unique population of patients.","PeriodicalId":16693,"journal":{"name":"Journal of Pediatric Hematology/Oncology","volume":" ","pages":"265-278"},"PeriodicalIF":0.9,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144475738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0